Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024312 (lymphopenia)
 4,859 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 89 cases of rheumatoid polyarthritis the number of B lymphocytes was shown by an immunofluorescence technique and the number T lymphocytes by a rosette test. 30 untreated polyarthritics were distinguished into two groups: in one there was no change in the number of T cellules; in the other there was a reduction in the number of T cells and lymphopenia. The same differences were found under corticotherapy (10 cases), antimalarial drugs (8 cases), penicillamine (21 cases), chrysotherapy (11 cases) and levamisole (9 cases). Levamisole only infrequently increases the number of T cellules (2/9). No relation with any developmental parameter was found in any group.
 ...
PMID:[Cellular immunity in rheumatoid arthritis. Effect of therapy]. 32 99

Eighty-two patients with squamous cells carcinoma of the oral cavity belonging to stages T1N0M0 and T2N0M0 were randomized to receive either levamisole or placebo therapy following conventional radiotherapy. Oral levamisole, at 150 mg daily doses for three consecutive days, was given once every two weeks. The patients were followed-up for three years and the results reported. Levamisole appears to have some beneficial effect in prolonging the disease-free interval of these patients (44% in the levamisole group compared to 32% in the placebo group after 30 months of therapy). This, however, did not have any effect of the metastatic potential of the tumors. The effects of levamisole on peripheral blood leukocytes and lymphocytes were more promising. The restoration of leukopenia and lymphopenia observed after radiotherapy was faster in the levamisole group when compared to the placebo group.
 ...
PMID:Role of levamisole immunotherapy as an adjuvant to radiotherapy in oral cancer. I. A three-year clinical follow up. 369 3

A placebo-controlled trial of Levamisole in 47 black children with measles is reported. The children were of satisfactory nutrition but at risk from severe disease as judged by a lymphopenia of less than 2000 X 10(-9)/m3 (less than 2000/mm3) early in the exanthem. A placebo or Levamisole (2.5 mg/kg/dose) were given orally weekly for six weeks. Death or persistence of radiological pneumonia at six weeks occurred in 74% of the Levamisole and 92% of the placebo group. No side effects of the drug were noted. The immune responses that were monitored for six weeks were total lymphocyte and lymphocyte subpopulation counts, PHA stimulated lymphocyte transformation, leucocyte migration inhibition, measles antibody titres and serum levels of immunoglobulins and complement components. In none of these was a significant difference found between the two groups. While there was a trend clinically towards complete recovery in the group that received Levamisole, statistically it was not significant, and therefore Levamisole cannot be recommended for treatment of measles.
 ...
PMID:Levamisole therapy in children at risk from severe measles. 618 87

Two hundred-eighty patients were randomized to receive either BCNU, hydroxyurea and imidazole carboxamide (BHD), BHD plus levamisole, or high-dose DTIC plus actinomycin D. There was no difference in response rate in the three groups (24%, 25% and 22%). Females responded better than males and, as expected, those with a better performance status responded more favorably than those with poor performance status. Patients whose primary site of melanoma was on the extremities did significantly better than those melanomas originating on the trunk or head and neck. Patients with lymphocyte counts greater than 2000/mm3 fared better than those with lymphopenia. Those responders who received high-dose DTIC plus actinomycin D had a significantly longer length of response than those receiving the immunotherapy limb. This was also true in those patients who had a prior disease-free interval of greater than 6 months before being placed in this study. Although there was no difference in survival from the start of treatment in all patients, those patients receiving high-dose DTIC plus actinomycin D and who had a prior disease-free interval of greater than 6 months, had significantly superior survival when compared to the immunotherapy limb. It is concluded that the addition of Levamisole to BHD does not improve response rate and may in certain subsets be detrimental to disease-free response and survival. High-dose DTIC plus actinomycin D is equally effective to BHD.
 ...
PMID:Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study. 636 30